Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

SAB Biotherapeutics Developed Novel SAB-176 Influenza Immunotherapy

SAB Biotherapeutics has developed novel SAB-176, an investigational drug for  post-exposure prophylaxis of influenza A and  B  in high-risk patients, including those with resistant strains of the virus.

SAB-176 is a highly effective immunotherapy based on the fundamentals of the innate immune response to neutralise influenza A and  B  viruses by generating endogenous antibodies that bind to multiple epitopes. 

The treatment is produced on patented DiversitAb™ platform, which allows for the first time rapid and large-scale production of highly potent fully human polyclonal IgG antibodies without the requirement of human donors.

Several clinical and pre-clinical studies such as Phase 1 trial in healthy volunteers and a Phase 2a challenge study that ended last year have shown that SAB-176 provides broad antibody protection against multiple strains of this rapidly evolving virus.

Influenza continues to cause serious health problems in the United States and around the world. SAB-176 consisting of multi-epitope targeting method has a clear difference compared to monoclonal antibodies (mAb) and can maintain its effectiveness against viral mutations in preventing or reducing the risk of treatment resistance influenza strains.

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) to SAB-176, an investigational therapeutic for the treatment of post-exposure prophylaxis of Type A and Type B influenza.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024